Nkarta Presents NKX019 Trial in Progress Poster at the 2021 ASH Annual Meeting and Exposition
13 déc. 2021 16h02 HE
|
Nkarta, Inc.
SOUTH SAN FRANCISCO, Calif., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer,...
Nkarta Presents New Preclinical Data from Engineered NK Cell Platform at SITC 36th Annual Meeting
12 nov. 2021 07h15 HE
|
Nkarta, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer,...
Nkarta Reports Third Quarter 2021 Financial Results and Business Update
10 nov. 2021 16h01 HE
|
Nkarta, Inc.
Initial data expected in 1H 2022 from Phase 1 clinical trial of NKX101 in AML and MDSSuccessful dosing of NKX019 in patients with B cell malignancies; initial Phase 1 clinical trial data expected in...
Nkarta to Participate at Upcoming Investor Conferences
04 nov. 2021 08h04 HE
|
Nkarta, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer,...
Nkarta Announces Updates to NKX019 and NKX101 Clinical Development Programs
07 oct. 2021 16h01 HE
|
Nkarta, Inc.
First patients dosed in Phase 1 clinical trial evaluating NKX019 in CD19+ advanced B cell malignanciesInitial data from the NKX019 clinical trial expected in 2022Initial data from Phase 1 clinical...
Nkarta to Present Preclinical Data from Engineered NK Cell Platform at SITC 36th Annual Meeting
01 oct. 2021 08h08 HE
|
Nkarta, Inc.
Data support potential clinical applications of CRISPR/Cas9 genome engineering, CD70 chimeric antigen receptor (CAR) targeting, and donor selection algorithms in next generation NK cell development...
Nkarta to Participate at Upcoming Investor Conference
14 sept. 2021 08h32 HE
|
Nkarta, Inc.
SOUTH SAN FRANCISCO, Calif., Sept. 14, 2021 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer,...
Nkarta Reports Second Quarter 2021 Financial Results and Business Progress
12 août 2021 16h02 HE
|
Nkarta, Inc.
Initial data from NKX101 clinical trial expected by end of 2021NKX019 patient dosing expected to start in 2H 2021Collaboration with CRISPR Therapeutics to develop gene-edited cell therapiesNew lease...
Nkarta Establishes New Combined NK Cell Therapy Manufacturing Facility / Company Headquarters
14 juil. 2021 07h00 HE
|
Nkarta, Inc.
88,000 square foot facility in South San Francisco will support scaled manufacturing of Nkarta’s engineered NK cell therapy candidates, and be home to company headquartersPlanned production expansion...
Nkarta to Present at Upcoming Investor Conference
16 juin 2021 07h00 HE
|
Nkarta, Inc.
SOUTH SAN FRANCISCO, Calif., June 16, 2021 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer,...